| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 452 | 2024 | 6882 | 30.810 |
Why?
|
| Psychotic Disorders | 283 | 2024 | 3046 | 28.910 |
Why?
|
| Schizophrenic Psychology | 133 | 2024 | 1678 | 13.890 |
Why?
|
| Bipolar Disorder | 134 | 2023 | 5027 | 7.950 |
Why?
|
| Psychiatry | 27 | 2023 | 1695 | 5.230 |
Why?
|
| Cognition Disorders | 79 | 2024 | 4043 | 5.210 |
Why?
|
| Antipsychotic Agents | 81 | 2024 | 3057 | 4.530 |
Why?
|
| Brain | 173 | 2023 | 26386 | 4.160 |
Why?
|
| Magnetic Resonance Imaging | 265 | 2023 | 35424 | 3.480 |
Why?
|
| Prefrontal Cortex | 58 | 2021 | 2147 | 3.380 |
Why?
|
| Child of Impaired Parents | 17 | 2012 | 455 | 3.230 |
Why?
|
| Cognition | 72 | 2024 | 6770 | 3.110 |
Why?
|
| Psychiatric Status Rating Scales | 108 | 2023 | 6038 | 3.090 |
Why?
|
| Frontal Lobe | 31 | 2018 | 1406 | 3.030 |
Why?
|
| Neuropsychological Tests | 116 | 2023 | 6994 | 2.840 |
Why?
|
| Mental Disorders | 37 | 2023 | 6600 | 2.770 |
Why?
|
| Temporal Lobe | 23 | 2018 | 1670 | 2.620 |
Why?
|
| Corpus Callosum | 28 | 2021 | 737 | 2.600 |
Why?
|
| Family | 44 | 2023 | 3147 | 2.460 |
Why?
|
| Neurosciences | 7 | 2023 | 348 | 2.410 |
Why?
|
| Humans | 820 | 2024 | 744376 | 2.330 |
Why?
|
| Amygdala | 20 | 2022 | 1315 | 2.270 |
Why?
|
| Endophenotypes | 16 | 2022 | 250 | 2.240 |
Why?
|
| Hippocampus | 22 | 2023 | 3675 | 2.180 |
Why?
|
| Social Perception | 14 | 2023 | 425 | 1.990 |
Why?
|
| Schizotypal Personality Disorder | 14 | 2013 | 288 | 1.940 |
Why?
|
| Theory of Mind | 8 | 2024 | 86 | 1.910 |
Why?
|
| Cerebral Cortex | 38 | 2022 | 5709 | 1.900 |
Why?
|
| Adult | 430 | 2024 | 214056 | 1.870 |
Why?
|
| Autistic Disorder | 26 | 2023 | 1185 | 1.820 |
Why?
|
| Nerve Net | 27 | 2021 | 2174 | 1.800 |
Why?
|
| Neurologic Examination | 17 | 2019 | 931 | 1.800 |
Why?
|
| Emotions | 26 | 2023 | 2658 | 1.800 |
Why?
|
| Adolescent | 264 | 2023 | 85784 | 1.790 |
Why?
|
| Social Behavior | 20 | 2022 | 1127 | 1.780 |
Why?
|
| Image Processing, Computer-Assisted | 73 | 2023 | 8949 | 1.760 |
Why?
|
| Male | 508 | 2024 | 350118 | 1.740 |
Why?
|
| Brain Mapping | 65 | 2023 | 6670 | 1.700 |
Why?
|
| Yoga | 4 | 2024 | 253 | 1.690 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 30 | 2017 | 1953 | 1.650 |
Why?
|
| Cholinergic Antagonists | 7 | 2023 | 165 | 1.630 |
Why?
|
| Magnetic Resonance Spectroscopy | 37 | 2018 | 3759 | 1.620 |
Why?
|
| Young Adult | 155 | 2023 | 56434 | 1.590 |
Why?
|
| Female | 480 | 2024 | 380200 | 1.580 |
Why?
|
| DiGeorge Syndrome | 11 | 2019 | 177 | 1.570 |
Why?
|
| Memory, Short-Term | 20 | 2023 | 977 | 1.560 |
Why?
|
| Meditation | 2 | 2024 | 242 | 1.510 |
Why?
|
| Social Adjustment | 14 | 2022 | 631 | 1.510 |
Why?
|
| Therapy, Computer-Assisted | 7 | 2017 | 274 | 1.490 |
Why?
|
| Family Health | 9 | 2015 | 1281 | 1.480 |
Why?
|
| Neurology | 4 | 2023 | 763 | 1.430 |
Why?
|
| Hallucinations | 11 | 2023 | 360 | 1.370 |
Why?
|
| Neural Pathways | 23 | 2021 | 2973 | 1.280 |
Why?
|
| Longitudinal Studies | 61 | 2023 | 13988 | 1.210 |
Why?
|
| Phenotype | 41 | 2023 | 16367 | 1.190 |
Why?
|
| Functional Laterality | 41 | 2016 | 2290 | 1.180 |
Why?
|
| Basal Ganglia | 11 | 2010 | 546 | 1.160 |
Why?
|
| Early Diagnosis | 15 | 2024 | 1184 | 1.160 |
Why?
|
| Pituitary Gland | 8 | 2015 | 665 | 1.150 |
Why?
|
| Choroid Plexus | 4 | 2023 | 231 | 1.140 |
Why?
|
| Evoked Potentials, Auditory | 11 | 2022 | 525 | 1.140 |
Why?
|
| Gyrus Cinguli | 22 | 2021 | 1091 | 1.130 |
Why?
|
| Thalamus | 16 | 2021 | 1023 | 1.110 |
Why?
|
| Nervous System Diseases | 12 | 2018 | 1622 | 1.090 |
Why?
|
| Organ Size | 22 | 2019 | 2251 | 1.060 |
Why?
|
| Clozapine | 4 | 2022 | 498 | 1.000 |
Why?
|
| Caregivers | 4 | 2022 | 2095 | 0.990 |
Why?
|
| Analysis of Variance | 44 | 2015 | 6366 | 0.970 |
Why?
|
| Diffusion Tensor Imaging | 11 | 2022 | 2305 | 0.960 |
Why?
|
| Genetic Predisposition to Disease | 41 | 2019 | 17445 | 0.940 |
Why?
|
| Saccades | 19 | 2022 | 246 | 0.940 |
Why?
|
| Risperidone | 16 | 2016 | 383 | 0.930 |
Why?
|
| Affective Disorders, Psychotic | 9 | 2021 | 191 | 0.930 |
Why?
|
| Cannabis | 4 | 2023 | 440 | 0.910 |
Why?
|
| Depressive Disorder | 27 | 2017 | 3748 | 0.890 |
Why?
|
| Siblings | 4 | 2015 | 854 | 0.890 |
Why?
|
| Aspartic Acid | 12 | 2015 | 576 | 0.870 |
Why?
|
| Neuronal Plasticity | 8 | 2021 | 1423 | 0.860 |
Why?
|
| Behavioral Symptoms | 3 | 2015 | 175 | 0.850 |
Why?
|
| Executive Function | 13 | 2022 | 1364 | 0.830 |
Why?
|
| Telemedicine | 9 | 2022 | 2872 | 0.820 |
Why?
|
| Interpersonal Relations | 4 | 2017 | 1425 | 0.820 |
Why?
|
| Pattern Recognition, Visual | 8 | 2021 | 824 | 0.820 |
Why?
|
| Intelligence | 7 | 2020 | 920 | 0.810 |
Why?
|
| Social Stigma | 4 | 2021 | 701 | 0.800 |
Why?
|
| Child | 128 | 2024 | 77708 | 0.790 |
Why?
|
| Neuropsychology | 2 | 2018 | 110 | 0.790 |
Why?
|
| Caudate Nucleus | 9 | 2016 | 393 | 0.790 |
Why?
|
| Pilot Projects | 30 | 2023 | 8319 | 0.790 |
Why?
|
| Emotional Intelligence | 5 | 2019 | 136 | 0.780 |
Why?
|
| Cerebellum | 11 | 2021 | 1488 | 0.780 |
Why?
|
| Reference Values | 34 | 2015 | 4982 | 0.770 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2014 | 957 | 0.750 |
Why?
|
| Mental Health | 9 | 2024 | 3014 | 0.750 |
Why?
|
| Motor Cortex | 3 | 2019 | 986 | 0.740 |
Why?
|
| Impulsive Behavior | 2 | 2015 | 316 | 0.740 |
Why?
|
| Electroencephalography | 37 | 2023 | 6150 | 0.730 |
Why?
|
| Principal Component Analysis | 7 | 2017 | 940 | 0.730 |
Why?
|
| Auditory Cortex | 6 | 2020 | 346 | 0.700 |
Why?
|
| Middle Aged | 164 | 2022 | 213388 | 0.700 |
Why?
|
| Mental Health Services | 6 | 2020 | 1643 | 0.690 |
Why?
|
| Risk | 23 | 2023 | 9688 | 0.690 |
Why?
|
| Pursuit, Smooth | 7 | 2019 | 41 | 0.690 |
Why?
|
| Obsessive-Compulsive Disorder | 14 | 2013 | 1444 | 0.690 |
Why?
|
| Glutamic Acid | 7 | 2023 | 1169 | 0.680 |
Why?
|
| Facial Expression | 9 | 2021 | 508 | 0.680 |
Why?
|
| Statistics as Topic | 17 | 2017 | 2373 | 0.670 |
Why?
|
| Evoked Potentials, Motor | 2 | 2019 | 454 | 0.660 |
Why?
|
| Retina | 2 | 2020 | 2616 | 0.660 |
Why?
|
| Thinking | 4 | 2023 | 318 | 0.660 |
Why?
|
| Case-Control Studies | 55 | 2020 | 21747 | 0.650 |
Why?
|
| Self Concept | 4 | 2013 | 1025 | 0.650 |
Why?
|
| Dominance, Cerebral | 19 | 2017 | 635 | 0.640 |
Why?
|
| Memory Disorders | 10 | 2015 | 1186 | 0.630 |
Why?
|
| Psychopathology | 7 | 2023 | 409 | 0.630 |
Why?
|
| Psychotherapy | 10 | 2024 | 1643 | 0.630 |
Why?
|
| Data Collection | 4 | 2021 | 3339 | 0.620 |
Why?
|
| Corpus Striatum | 11 | 2021 | 1221 | 0.620 |
Why?
|
| Interdisciplinary Communication | 3 | 2020 | 950 | 0.620 |
Why?
|
| Phospholipids | 11 | 2013 | 784 | 0.620 |
Why?
|
| Health Services Accessibility | 6 | 2020 | 5135 | 0.620 |
Why?
|
| Evoked Potentials | 9 | 2023 | 1056 | 0.620 |
Why?
|
| Awareness | 7 | 2017 | 640 | 0.610 |
Why?
|
| Social Control, Formal | 1 | 2018 | 110 | 0.610 |
Why?
|
| Models, Psychological | 9 | 2015 | 811 | 0.610 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2020 | 15520 | 0.600 |
Why?
|
| Catechol O-Methyltransferase | 6 | 2020 | 245 | 0.600 |
Why?
|
| Delusions | 9 | 2022 | 300 | 0.590 |
Why?
|
| Parahippocampal Gyrus | 5 | 2016 | 116 | 0.590 |
Why?
|
| Visual Cortex | 3 | 2022 | 1149 | 0.590 |
Why?
|
| Sleep, REM | 12 | 2007 | 595 | 0.590 |
Why?
|
| Risk Factors | 59 | 2023 | 72295 | 0.590 |
Why?
|
| Group Homes | 1 | 2016 | 34 | 0.580 |
Why?
|
| Suicide | 6 | 2013 | 1474 | 0.570 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 1431 | 0.570 |
Why?
|
| Protons | 4 | 2013 | 1127 | 0.570 |
Why?
|
| Alcoholism | 7 | 2014 | 1906 | 0.570 |
Why?
|
| Antimanic Agents | 4 | 2014 | 522 | 0.560 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2016 | 552 | 0.560 |
Why?
|
| Sex Characteristics | 13 | 2021 | 2585 | 0.560 |
Why?
|
| Cross-Cultural Comparison | 4 | 2016 | 651 | 0.550 |
Why?
|
| Religion and Psychology | 3 | 2014 | 171 | 0.550 |
Why?
|
| Comprehension | 3 | 2019 | 610 | 0.550 |
Why?
|
| Electromyography | 3 | 2018 | 1379 | 0.550 |
Why?
|
| Occipital Lobe | 4 | 2015 | 379 | 0.550 |
Why?
|
| Event-Related Potentials, P300 | 6 | 2023 | 150 | 0.540 |
Why?
|
| Transcranial Magnetic Stimulation | 6 | 2022 | 1432 | 0.540 |
Why?
|
| Nerve Fibers, Unmyelinated | 3 | 2012 | 98 | 0.540 |
Why?
|
| Psychoses, Substance-Induced | 3 | 2019 | 96 | 0.530 |
Why?
|
| Disease Progression | 18 | 2022 | 13285 | 0.530 |
Why?
|
| Visual Pathways | 1 | 2020 | 565 | 0.530 |
Why?
|
| Stress Disorders, Post-Traumatic | 10 | 2023 | 4266 | 0.520 |
Why?
|
| Koro | 1 | 2014 | 1 | 0.520 |
Why?
|
| Verbal Learning | 4 | 2013 | 468 | 0.510 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2010 | 604 | 0.510 |
Why?
|
| Hinduism | 1 | 2014 | 14 | 0.500 |
Why?
|
| Anxiety Disorders | 8 | 2017 | 2690 | 0.490 |
Why?
|
| Factor Analysis, Statistical | 10 | 2019 | 977 | 0.490 |
Why?
|
| Reaction Time | 24 | 2014 | 2098 | 0.490 |
Why?
|
| Parietal Lobe | 7 | 2019 | 838 | 0.490 |
Why?
|
| Marijuana Abuse | 3 | 2022 | 403 | 0.480 |
Why?
|
| Sleep Stages | 11 | 2005 | 686 | 0.480 |
Why?
|
| Multifactorial Inheritance | 4 | 2022 | 1194 | 0.470 |
Why?
|
| Art | 1 | 2014 | 65 | 0.470 |
Why?
|
| Task Performance and Analysis | 3 | 2017 | 780 | 0.470 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 10 | 2021 | 3658 | 0.470 |
Why?
|
| Age of Onset | 16 | 2022 | 3270 | 0.470 |
Why?
|
| Learning | 6 | 2019 | 1712 | 0.470 |
Why?
|
| Philosophy | 2 | 2024 | 66 | 0.460 |
Why?
|
| Drama | 1 | 2013 | 13 | 0.460 |
Why?
|
| Tomography, Optical Coherence | 3 | 2022 | 2657 | 0.460 |
Why?
|
| Sleep | 5 | 2021 | 4623 | 0.450 |
Why?
|
| Lithium Compounds | 1 | 2014 | 225 | 0.450 |
Why?
|
| Dyskinesia, Drug-Induced | 3 | 2009 | 163 | 0.450 |
Why?
|
| Brain Diseases | 6 | 2023 | 1563 | 0.440 |
Why?
|
| Peer Group | 2 | 2017 | 635 | 0.440 |
Why?
|
| Memory | 8 | 2013 | 2174 | 0.440 |
Why?
|
| Delta Rhythm | 4 | 2015 | 78 | 0.440 |
Why?
|
| Imaging, Three-Dimensional | 10 | 2023 | 4042 | 0.440 |
Why?
|
| Judgment | 2 | 2021 | 281 | 0.440 |
Why?
|
| Attention | 20 | 2019 | 2397 | 0.430 |
Why?
|
| Environment | 2 | 2016 | 1123 | 0.430 |
Why?
|
| Hepatic Encephalopathy | 1 | 2014 | 139 | 0.430 |
Why?
|
| Suicide, Attempted | 5 | 2015 | 1218 | 0.430 |
Why?
|
| Psychomotor Performance | 14 | 2022 | 1901 | 0.420 |
Why?
|
| Psychometrics | 11 | 2020 | 3002 | 0.420 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3135 | 0.410 |
Why?
|
| Editorial Policies | 1 | 2016 | 451 | 0.410 |
Why?
|
| Self Care | 1 | 2017 | 786 | 0.410 |
Why?
|
| Culture | 3 | 2011 | 633 | 0.410 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3242 | 0.410 |
Why?
|
| Hospitals, Psychiatric | 2 | 2012 | 332 | 0.400 |
Why?
|
| Genetics | 1 | 2012 | 112 | 0.400 |
Why?
|
| Limbic System | 7 | 2021 | 426 | 0.400 |
Why?
|
| Science | 1 | 2014 | 241 | 0.400 |
Why?
|
| Behavior Therapy | 1 | 2017 | 865 | 0.390 |
Why?
|
| Asia | 4 | 2014 | 609 | 0.390 |
Why?
|
| Polysomnography | 8 | 2011 | 1776 | 0.390 |
Why?
|
| Personal Construct Theory | 2 | 2007 | 8 | 0.390 |
Why?
|
| Child Abuse | 10 | 2017 | 1030 | 0.390 |
Why?
|
| Psychotropic Drugs | 4 | 2015 | 894 | 0.390 |
Why?
|
| Financing, Organized | 1 | 2013 | 202 | 0.390 |
Why?
|
| Language | 5 | 2021 | 1471 | 0.390 |
Why?
|
| Mathematical Computing | 2 | 2008 | 147 | 0.390 |
Why?
|
| Adaptation, Psychological | 4 | 2018 | 2575 | 0.390 |
Why?
|
| Oxygen | 15 | 2017 | 4189 | 0.390 |
Why?
|
| Depressive Disorder, Major | 16 | 2024 | 4644 | 0.390 |
Why?
|
| Membrane Lipids | 6 | 2006 | 249 | 0.380 |
Why?
|
| Encephalitis | 1 | 2014 | 425 | 0.380 |
Why?
|
| Follow-Up Studies | 36 | 2021 | 39052 | 0.380 |
Why?
|
| Writing | 1 | 2013 | 206 | 0.380 |
Why?
|
| Chromosomes, Human, Pair 22 | 5 | 2013 | 351 | 0.380 |
Why?
|
| Anxiety | 5 | 2020 | 4296 | 0.380 |
Why?
|
| Brain Waves | 5 | 2015 | 401 | 0.370 |
Why?
|
| Reproducibility of Results | 22 | 2023 | 19905 | 0.370 |
Why?
|
| Septum Pellucidum | 2 | 2008 | 58 | 0.370 |
Why?
|
| Depression | 8 | 2019 | 7766 | 0.370 |
Why?
|
| Mentors | 1 | 2015 | 631 | 0.360 |
Why?
|
| RGS Proteins | 2 | 2013 | 77 | 0.360 |
Why?
|
| Paintings | 2 | 2014 | 101 | 0.360 |
Why?
|
| Inpatients | 2 | 2021 | 2518 | 0.360 |
Why?
|
| Disease Management | 2 | 2018 | 2460 | 0.360 |
Why?
|
| Computer-Assisted Instruction | 2 | 2010 | 365 | 0.360 |
Why?
|
| History, 20th Century | 7 | 2018 | 2740 | 0.350 |
Why?
|
| Heart Rate | 6 | 2019 | 4091 | 0.350 |
Why?
|
| Massachusetts | 5 | 2024 | 8662 | 0.350 |
Why?
|
| Internship and Residency | 5 | 2020 | 5789 | 0.350 |
Why?
|
| Cell Membrane | 6 | 2011 | 3749 | 0.350 |
Why?
|
| Treatment Outcome | 31 | 2022 | 63115 | 0.350 |
Why?
|
| Benzodiazepines | 8 | 2020 | 1101 | 0.340 |
Why?
|
| Antioxidants | 3 | 2018 | 1659 | 0.340 |
Why?
|
| History, 21st Century | 6 | 2018 | 1534 | 0.340 |
Why?
|
| Terminology as Topic | 3 | 2013 | 1547 | 0.340 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2019 | 719 | 0.330 |
Why?
|
| Severity of Illness Index | 30 | 2021 | 15535 | 0.330 |
Why?
|
| Music | 4 | 2020 | 263 | 0.330 |
Why?
|
| Psychopharmacology | 1 | 2010 | 143 | 0.330 |
Why?
|
| Personality Assessment | 3 | 2008 | 647 | 0.330 |
Why?
|
| Feasibility Studies | 9 | 2020 | 5077 | 0.330 |
Why?
|
| Epidemics | 1 | 2014 | 523 | 0.330 |
Why?
|
| Phosphorus Isotopes | 5 | 2010 | 126 | 0.330 |
Why?
|
| Anisotropy | 8 | 2022 | 1265 | 0.330 |
Why?
|
| Sex Factors | 21 | 2010 | 10400 | 0.330 |
Why?
|
| Recovery of Function | 1 | 2019 | 2926 | 0.320 |
Why?
|
| Bullying | 2 | 2022 | 210 | 0.320 |
Why?
|
| Affect | 7 | 2019 | 1475 | 0.320 |
Why?
|
| Problem Solving | 2 | 2008 | 440 | 0.320 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 658 | 0.320 |
Why?
|
| Speech Disorders | 1 | 2009 | 189 | 0.320 |
Why?
|
| Oxytocin | 3 | 2018 | 394 | 0.320 |
Why?
|
| Drug Discovery | 1 | 2016 | 1058 | 0.320 |
Why?
|
| China | 9 | 2020 | 2245 | 0.320 |
Why?
|
| Spirituality | 1 | 2012 | 405 | 0.320 |
Why?
|
| Reflex | 3 | 2006 | 365 | 0.310 |
Why?
|
| Affective Symptoms | 4 | 2019 | 407 | 0.310 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2018 | 3511 | 0.310 |
Why?
|
| Receptors, Neurotransmitter | 2 | 2008 | 178 | 0.310 |
Why?
|
| Time Factors | 28 | 2024 | 40077 | 0.310 |
Why?
|
| Grief | 2 | 2007 | 248 | 0.310 |
Why?
|
| Age Factors | 31 | 2023 | 18373 | 0.310 |
Why?
|
| Visual Perception | 7 | 2017 | 1420 | 0.310 |
Why?
|
| Speech Perception | 2 | 2016 | 490 | 0.300 |
Why?
|
| Prognosis | 17 | 2022 | 29060 | 0.300 |
Why?
|
| Dibenzothiazepines | 1 | 2007 | 103 | 0.300 |
Why?
|
| Cerebral Ventricles | 6 | 2001 | 544 | 0.300 |
Why?
|
| Neurobiology | 1 | 2008 | 121 | 0.300 |
Why?
|
| Rest | 6 | 2018 | 901 | 0.290 |
Why?
|
| Research | 3 | 2013 | 1999 | 0.290 |
Why?
|
| Cluster Analysis | 4 | 2022 | 2715 | 0.290 |
Why?
|
| Schizophrenia, Paranoid | 2 | 2020 | 104 | 0.290 |
Why?
|
| Violence | 2 | 2013 | 909 | 0.290 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2009 | 231 | 0.290 |
Why?
|
| Pharmacogenetics | 3 | 2016 | 674 | 0.290 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2006 | 33 | 0.290 |
Why?
|
| Chromosome Deletion | 5 | 2013 | 1401 | 0.290 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2008 | 322 | 0.290 |
Why?
|
| Medicine | 1 | 2015 | 946 | 0.290 |
Why?
|
| History, Ancient | 3 | 2017 | 212 | 0.280 |
Why?
|
| Phosphocreatine | 7 | 2010 | 269 | 0.270 |
Why?
|
| Intelligence Tests | 5 | 2024 | 505 | 0.270 |
Why?
|
| Lithium | 7 | 2005 | 601 | 0.270 |
Why?
|
| North America | 7 | 2023 | 1249 | 0.270 |
Why?
|
| Pandemics | 3 | 2020 | 8386 | 0.270 |
Why?
|
| Language Disorders | 3 | 2013 | 141 | 0.270 |
Why?
|
| Conversion Disorder | 3 | 2019 | 205 | 0.270 |
Why?
|
| Cortical Synchronization | 1 | 2005 | 79 | 0.260 |
Why?
|
| Arginine Vasopressin | 2 | 2017 | 130 | 0.260 |
Why?
|
| Phosphorus | 6 | 2008 | 338 | 0.260 |
Why?
|
| Quinolones | 1 | 2009 | 367 | 0.260 |
Why?
|
| Hepatitis C, Chronic | 1 | 2014 | 1031 | 0.260 |
Why?
|
| Cannabinoids | 1 | 2008 | 166 | 0.260 |
Why?
|
| Predictive Value of Tests | 12 | 2021 | 15078 | 0.260 |
Why?
|
| Genetic Variation | 8 | 2018 | 6542 | 0.260 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2007 | 1107 | 0.260 |
Why?
|
| Beta Rhythm | 3 | 2019 | 58 | 0.260 |
Why?
|
| Haloperidol | 9 | 2009 | 397 | 0.260 |
Why?
|
| Genotype | 16 | 2020 | 12952 | 0.260 |
Why?
|
| Acoustic Stimulation | 9 | 2021 | 1216 | 0.250 |
Why?
|
| Antidepressive Agents | 3 | 2016 | 2838 | 0.250 |
Why?
|
| Receptors, Metabotropic Glutamate | 3 | 2016 | 211 | 0.250 |
Why?
|
| Hyperglycemia | 2 | 2020 | 1373 | 0.250 |
Why?
|
| Auditory Pathways | 2 | 2021 | 233 | 0.250 |
Why?
|
| Famous Persons | 1 | 2006 | 108 | 0.250 |
Why?
|
| Brief Psychiatric Rating Scale | 7 | 2011 | 108 | 0.250 |
Why?
|
| Education, Medical | 2 | 2014 | 1722 | 0.250 |
Why?
|
| Curriculum | 2 | 2015 | 3605 | 0.240 |
Why?
|
| Herpesvirus 1, Human | 4 | 2012 | 743 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 3 | 2013 | 7281 | 0.240 |
Why?
|
| Aging | 8 | 2021 | 8663 | 0.240 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 1998 | 434 | 0.240 |
Why?
|
| Photic Stimulation | 11 | 2017 | 2026 | 0.240 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2001 | 139 | 0.230 |
Why?
|
| History, 19th Century | 3 | 2017 | 720 | 0.230 |
Why?
|
| Putamen | 9 | 2019 | 291 | 0.230 |
Why?
|
| Lithium Chloride | 2 | 2002 | 87 | 0.230 |
Why?
|
| Research Design | 5 | 2016 | 5986 | 0.230 |
Why?
|
| Dopamine | 6 | 2007 | 1591 | 0.230 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 434 | 0.230 |
Why?
|
| Quality of Life | 5 | 2024 | 12803 | 0.230 |
Why?
|
| Inflammation | 4 | 2023 | 10636 | 0.220 |
Why?
|
| Chi-Square Distribution | 9 | 2012 | 3508 | 0.220 |
Why?
|
| Drug Tolerance | 1 | 2004 | 376 | 0.220 |
Why?
|
| Brain Stem | 6 | 2013 | 846 | 0.220 |
Why?
|
| Entorhinal Cortex | 1 | 2004 | 272 | 0.220 |
Why?
|
| Models, Statistical | 4 | 2018 | 5101 | 0.220 |
Why?
|
| Receptors, Muscarinic | 2 | 2012 | 156 | 0.220 |
Why?
|
| Spin Labels | 2 | 2023 | 332 | 0.220 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1999 | 126 | 0.220 |
Why?
|
| Heart Diseases | 1 | 2016 | 2789 | 0.220 |
Why?
|
| Professional Competence | 1 | 2006 | 447 | 0.210 |
Why?
|
| Apolipoproteins | 1 | 2005 | 317 | 0.210 |
Why?
|
| Pituitary-Adrenal System | 4 | 2013 | 553 | 0.210 |
Why?
|
| Glutathione | 2 | 2018 | 590 | 0.210 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 3842 | 0.210 |
Why?
|
| Neurotransmitter Agents | 3 | 2011 | 647 | 0.210 |
Why?
|
| Expressed Emotion | 1 | 2022 | 92 | 0.210 |
Why?
|
| Phosphates | 2 | 2004 | 785 | 0.210 |
Why?
|
| Syndrome | 4 | 2023 | 3252 | 0.210 |
Why?
|
| Risk Assessment | 6 | 2022 | 23336 | 0.210 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 6 | 2023 | 2737 | 0.210 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2022 | 65 | 0.210 |
Why?
|
| India | 7 | 2016 | 2197 | 0.210 |
Why?
|
| Self Report | 6 | 2022 | 3557 | 0.200 |
Why?
|
| Atrophy | 6 | 2016 | 1584 | 0.200 |
Why?
|
| Mood Disorders | 6 | 2017 | 1106 | 0.200 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 1988 | 632 | 0.200 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2013 | 703 | 0.200 |
Why?
|
| Cerebellar Nuclei | 1 | 2021 | 52 | 0.200 |
Why?
|
| Creatine | 7 | 2015 | 421 | 0.200 |
Why?
|
| Personality Disorders | 2 | 2005 | 713 | 0.200 |
Why?
|
| Panic Disorder | 1 | 2005 | 616 | 0.200 |
Why?
|
| Disease Susceptibility | 3 | 2021 | 1782 | 0.200 |
Why?
|
| Obstetric Labor Complications | 1 | 2003 | 238 | 0.200 |
Why?
|
| Knowledge | 1 | 2023 | 181 | 0.200 |
Why?
|
| Energy Metabolism | 6 | 2012 | 2897 | 0.190 |
Why?
|
| Cerebrovascular Circulation | 4 | 2023 | 2732 | 0.190 |
Why?
|
| Multilingualism | 1 | 2021 | 87 | 0.190 |
Why?
|
| Fluphenazine | 3 | 2009 | 36 | 0.190 |
Why?
|
| Linear Models | 8 | 2019 | 5952 | 0.190 |
Why?
|
| Physicians | 2 | 2016 | 4567 | 0.190 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2021 | 117 | 0.190 |
Why?
|
| Lorazepam | 3 | 2002 | 145 | 0.190 |
Why?
|
| Internal-External Control | 3 | 2008 | 363 | 0.190 |
Why?
|
| Tomography, Emission-Computed | 4 | 1999 | 1144 | 0.190 |
Why?
|
| Ocular Motility Disorders | 2 | 2013 | 135 | 0.180 |
Why?
|
| Arecoline | 3 | 1988 | 9 | 0.180 |
Why?
|
| Deception | 1 | 2021 | 99 | 0.180 |
Why?
|
| Individuality | 2 | 2021 | 307 | 0.180 |
Why?
|
| Transients and Migrants | 1 | 2022 | 155 | 0.180 |
Why?
|
| Fatty Acids, Unsaturated | 3 | 2013 | 546 | 0.180 |
Why?
|
| Clonidine | 3 | 2001 | 164 | 0.180 |
Why?
|
| Social Participation | 2 | 2023 | 173 | 0.180 |
Why?
|
| Pleasure | 1 | 2019 | 41 | 0.180 |
Why?
|
| Eye Movements | 7 | 2017 | 507 | 0.170 |
Why?
|
| Logistic Models | 4 | 2024 | 13409 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2007 | 1359 | 0.170 |
Why?
|
| Adolescent Development | 3 | 2013 | 278 | 0.170 |
Why?
|
| Prospective Studies | 15 | 2023 | 53291 | 0.170 |
Why?
|
| Clomipramine | 2 | 1998 | 54 | 0.170 |
Why?
|
| Glutamine | 3 | 2023 | 579 | 0.170 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 25041 | 0.170 |
Why?
|
| Genome-Wide Association Study | 8 | 2021 | 12262 | 0.170 |
Why?
|
| Panic | 3 | 1989 | 106 | 0.170 |
Why?
|
| Neural Inhibition | 4 | 2009 | 602 | 0.170 |
Why?
|
| Remedial Teaching | 2 | 2010 | 13 | 0.170 |
Why?
|
| Reflex, Abnormal | 1 | 2019 | 85 | 0.170 |
Why?
|
| Program Development | 2 | 2018 | 1316 | 0.170 |
Why?
|
| Substance-Related Disorders | 5 | 2022 | 4257 | 0.170 |
Why?
|
| Autonomic Nervous System | 2 | 2019 | 671 | 0.170 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2019 | 126 | 0.170 |
Why?
|
| Psychophysiologic Disorders | 2 | 2017 | 228 | 0.170 |
Why?
|
| Erythrocyte Membrane | 3 | 2004 | 442 | 0.170 |
Why?
|
| Hallucinogens | 1 | 2022 | 180 | 0.170 |
Why?
|
| Insulin-Secreting Cells | 1 | 2006 | 892 | 0.170 |
Why?
|
| Neurophysins | 1 | 2018 | 14 | 0.170 |
Why?
|
| Minority Groups | 2 | 2023 | 1220 | 0.160 |
Why?
|
| Asperger Syndrome | 2 | 2010 | 63 | 0.160 |
Why?
|
| Abnormalities, Multiple | 3 | 2013 | 1416 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2022 | 616 | 0.160 |
Why?
|
| Internet | 3 | 2016 | 3064 | 0.160 |
Why?
|
| Lateral Ventricles | 1 | 2019 | 147 | 0.160 |
Why?
|
| Attitude | 2 | 2021 | 776 | 0.160 |
Why?
|
| Pregnenolone | 1 | 2018 | 26 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 3020 | 0.160 |
Why?
|
| Ownership | 1 | 2021 | 332 | 0.160 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2013 | 475 | 0.160 |
Why?
|
| Piperazines | 1 | 2009 | 2488 | 0.160 |
Why?
|
| Teaching | 2 | 2020 | 1174 | 0.160 |
Why?
|
| Regression Analysis | 4 | 2021 | 6459 | 0.160 |
Why?
|
| Dopamine Agents | 1 | 1999 | 189 | 0.160 |
Why?
|
| Catatonia | 2 | 2019 | 158 | 0.160 |
Why?
|
| Purines | 2 | 2012 | 594 | 0.150 |
Why?
|
| Nerve Fibers | 2 | 2020 | 687 | 0.150 |
Why?
|
| Motion Perception | 2 | 2020 | 408 | 0.150 |
Why?
|
| Alcohol-Related Disorders | 1 | 2000 | 234 | 0.150 |
Why?
|
| Journalism, Medical | 1 | 2018 | 74 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2013 | 4244 | 0.150 |
Why?
|
| Hydrocortisone | 6 | 2018 | 1826 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2019 | 380 | 0.150 |
Why?
|
| Personal Autonomy | 1 | 2020 | 298 | 0.150 |
Why?
|
| Neocortex | 2 | 2020 | 400 | 0.150 |
Why?
|
| Microvessels | 1 | 2022 | 544 | 0.150 |
Why?
|
| Pregnanolone | 1 | 2018 | 62 | 0.150 |
Why?
|
| Adenosine Triphosphate | 4 | 2010 | 2027 | 0.150 |
Why?
|
| Brain Chemistry | 4 | 2003 | 982 | 0.150 |
Why?
|
| Remission Induction | 2 | 2022 | 2386 | 0.150 |
Why?
|
| Auditory Perceptual Disorders | 1 | 1997 | 36 | 0.150 |
Why?
|
| Neostriatum | 2 | 2014 | 250 | 0.150 |
Why?
|
| Independent Living | 2 | 2020 | 568 | 0.150 |
Why?
|
| Models, Neurological | 5 | 2017 | 1775 | 0.150 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2017 | 107 | 0.150 |
Why?
|
| Water | 2 | 2020 | 1395 | 0.150 |
Why?
|
| 22q11 Deletion Syndrome | 1 | 2016 | 17 | 0.140 |
Why?
|
| Personality | 2 | 2018 | 552 | 0.140 |
Why?
|
| Vasopressins | 1 | 2018 | 370 | 0.140 |
Why?
|
| Acetylcysteine | 1 | 2018 | 271 | 0.140 |
Why?
|
| Statistics, Nonparametric | 6 | 2017 | 2887 | 0.140 |
Why?
|
| Genetic Association Studies | 5 | 2019 | 2703 | 0.140 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2022 | 1683 | 0.140 |
Why?
|
| Retinal Vessels | 1 | 2022 | 772 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2012 | 3309 | 0.140 |
Why?
|
| Motivation | 3 | 2014 | 1971 | 0.140 |
Why?
|
| Drug Administration Schedule | 4 | 2009 | 4933 | 0.140 |
Why?
|
| Ecosystem | 1 | 2020 | 474 | 0.140 |
Why?
|
| Herpes Simplex | 2 | 2012 | 470 | 0.140 |
Why?
|
| Attitude to Health | 2 | 2007 | 2052 | 0.140 |
Why?
|
| Erythrocytes | 2 | 2005 | 2455 | 0.140 |
Why?
|
| Dissociative Disorders | 1 | 2018 | 231 | 0.140 |
Why?
|
| Child Development Disorders, Pervasive | 2 | 2013 | 615 | 0.140 |
Why?
|
| Single-Blind Method | 3 | 2023 | 1591 | 0.130 |
Why?
|
| Recurrence | 6 | 2021 | 8340 | 0.130 |
Why?
|
| Encyclopedias as Topic | 1 | 2015 | 20 | 0.130 |
Why?
|
| Interview, Psychological | 5 | 2018 | 812 | 0.130 |
Why?
|
| Complement System Proteins | 1 | 2019 | 795 | 0.130 |
Why?
|
| Imagination | 1 | 1997 | 221 | 0.130 |
Why?
|
| Needs Assessment | 2 | 2019 | 1146 | 0.130 |
Why?
|
| Serotonin | 4 | 2009 | 1017 | 0.130 |
Why?
|
| Receptors, Glutamate | 1 | 2016 | 232 | 0.130 |
Why?
|
| Movement Disorders | 2 | 2018 | 446 | 0.130 |
Why?
|
| Aged | 30 | 2021 | 163284 | 0.130 |
Why?
|
| Prolactin | 2 | 2008 | 669 | 0.130 |
Why?
|
| Referral and Consultation | 3 | 2021 | 3529 | 0.130 |
Why?
|
| Psychosomatic Medicine | 1 | 2015 | 75 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 850 | 0.130 |
Why?
|
| Galvanic Skin Response | 1 | 2017 | 349 | 0.130 |
Why?
|
| Computers, Handheld | 1 | 2017 | 208 | 0.130 |
Why?
|
| Computer Security | 1 | 2017 | 262 | 0.120 |
Why?
|
| Neuropsychiatry | 1 | 2015 | 55 | 0.120 |
Why?
|
| Histamine Antagonists | 1 | 2015 | 93 | 0.120 |
Why?
|
| Geographic Information Systems | 1 | 2017 | 281 | 0.120 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 1081 | 0.120 |
Why?
|
| Synaptic Transmission | 4 | 2020 | 1178 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 5 | 2018 | 2716 | 0.120 |
Why?
|
| Monitoring, Physiologic | 2 | 2019 | 1739 | 0.120 |
Why?
|
| Role | 1 | 2015 | 175 | 0.120 |
Why?
|
| Calcium Channels, L-Type | 1 | 2015 | 240 | 0.120 |
Why?
|
| Protein Precursors | 1 | 2018 | 1154 | 0.120 |
Why?
|
| United States | 10 | 2024 | 69869 | 0.120 |
Why?
|
| Phobic Disorders | 2 | 1986 | 439 | 0.120 |
Why?
|
| Body Temperature | 1 | 2017 | 777 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 11725 | 0.120 |
Why?
|
| Speech | 2 | 2017 | 541 | 0.120 |
Why?
|
| Animals | 13 | 2018 | 168770 | 0.120 |
Why?
|
| Theta Rhythm | 1 | 2015 | 207 | 0.120 |
Why?
|
| Schools | 1 | 2022 | 1433 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2017 | 3326 | 0.110 |
Why?
|
| Language Tests | 2 | 2013 | 202 | 0.110 |
Why?
|
| Progesterone | 1 | 2018 | 775 | 0.110 |
Why?
|
| Medical Informatics Applications | 1 | 2015 | 186 | 0.110 |
Why?
|
| Neuroleptic Malignant Syndrome | 2 | 1994 | 71 | 0.110 |
Why?
|
| Kynurenine | 2 | 2011 | 139 | 0.110 |
Why?
|
| Actigraphy | 1 | 2017 | 488 | 0.110 |
Why?
|
| Thyrotropin-Releasing Hormone | 3 | 1988 | 147 | 0.110 |
Why?
|
| Databases as Topic | 1 | 2015 | 475 | 0.110 |
Why?
|
| Outpatients | 4 | 2024 | 1487 | 0.110 |
Why?
|
| Valine | 2 | 2012 | 413 | 0.110 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 14723 | 0.110 |
Why?
|
| Synapses | 3 | 2007 | 1728 | 0.110 |
Why?
|
| Cholinesterases | 1 | 1992 | 34 | 0.110 |
Why?
|
| Space Perception | 2 | 2006 | 475 | 0.110 |
Why?
|
| Clinical Protocols | 2 | 2016 | 1462 | 0.110 |
Why?
|
| Radionuclide Imaging | 2 | 2010 | 2031 | 0.110 |
Why?
|
| Benzazepines | 1 | 2015 | 326 | 0.110 |
Why?
|
| Ego | 1 | 2012 | 96 | 0.110 |
Why?
|
| Social Environment | 3 | 2008 | 1023 | 0.110 |
Why?
|
| Residence Characteristics | 2 | 2020 | 2050 | 0.110 |
Why?
|
| Oxidation-Reduction | 3 | 2018 | 2184 | 0.110 |
Why?
|
| Confidentiality | 1 | 2017 | 612 | 0.110 |
Why?
|
| Plasmalogens | 1 | 2012 | 30 | 0.110 |
Why?
|
| Regional Health Planning | 1 | 2013 | 97 | 0.110 |
Why?
|
| Health Care Costs | 2 | 2022 | 3209 | 0.100 |
Why?
|
| Anti-Anxiety Agents | 2 | 2002 | 390 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2007 | 6077 | 0.100 |
Why?
|
| Ecology | 1 | 2012 | 106 | 0.100 |
Why?
|
| Electroconvulsive Therapy | 3 | 1994 | 477 | 0.100 |
Why?
|
| Pineal Gland | 1 | 2013 | 166 | 0.100 |
Why?
|
| Electrooculography | 3 | 2008 | 118 | 0.100 |
Why?
|
| Regional Blood Flow | 2 | 2007 | 1525 | 0.100 |
Why?
|
| Education | 1 | 2015 | 543 | 0.100 |
Why?
|
| Motor Activity | 3 | 2018 | 2715 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 18034 | 0.100 |
Why?
|
| Receptors, AMPA | 1 | 2013 | 332 | 0.100 |
Why?
|
| Parents | 2 | 2023 | 3405 | 0.100 |
Why?
|
| Wechsler Scales | 3 | 2008 | 260 | 0.100 |
Why?
|
| Insulin | 1 | 2006 | 6582 | 0.100 |
Why?
|
| Creatine Kinase | 1 | 1994 | 694 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 1 | 2018 | 1005 | 0.100 |
Why?
|
| Dexamethasone | 2 | 1989 | 1951 | 0.100 |
Why?
|
| Remote Consultation | 1 | 2014 | 238 | 0.100 |
Why?
|
| Portraits as Topic | 1 | 2011 | 33 | 0.100 |
Why?
|
| Evoked Potentials, Visual | 3 | 2023 | 427 | 0.100 |
Why?
|
| Acyclovir | 1 | 2012 | 272 | 0.100 |
Why?
|
| Drug Therapy, Combination | 5 | 2012 | 6489 | 0.100 |
Why?
|
| Dreams | 2 | 1990 | 147 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2003 | 2029 | 0.100 |
Why?
|
| Observer Variation | 4 | 2018 | 2593 | 0.100 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 5321 | 0.100 |
Why?
|
| Cephalometry | 2 | 2004 | 382 | 0.100 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2011 | 60 | 0.100 |
Why?
|
| Social Class | 3 | 2013 | 1997 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 9957 | 0.100 |
Why?
|
| Sample Size | 2 | 2020 | 845 | 0.100 |
Why?
|
| Desipramine | 2 | 1988 | 184 | 0.100 |
Why?
|
| Object Attachment | 1 | 2014 | 313 | 0.100 |
Why?
|
| Negotiating | 1 | 2012 | 133 | 0.090 |
Why?
|
| Elephants | 1 | 2011 | 38 | 0.090 |
Why?
|
| Employment | 1 | 2017 | 1132 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2009 | 10943 | 0.090 |
Why?
|
| Tryptophan | 2 | 2011 | 478 | 0.090 |
Why?
|
| Oxidative Stress | 3 | 2011 | 3084 | 0.090 |
Why?
|
| Health Surveys | 1 | 2021 | 4036 | 0.090 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 676 | 0.090 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 238 | 0.090 |
Why?
|
| Social Support | 3 | 2010 | 2118 | 0.090 |
Why?
|
| Acyltransferases | 1 | 2012 | 294 | 0.090 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2012 | 315 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 5390 | 0.090 |
Why?
|
| Chromatography, Gas | 3 | 2005 | 156 | 0.090 |
Why?
|
| Receptors, Cholinergic | 2 | 1988 | 238 | 0.090 |
Why?
|
| Semantics | 2 | 2013 | 585 | 0.090 |
Why?
|
| Anemia, Hypochromic | 1 | 1989 | 66 | 0.090 |
Why?
|
| Fear | 2 | 1989 | 1440 | 0.090 |
Why?
|
| Dipeptides | 1 | 2012 | 409 | 0.090 |
Why?
|
| Auditory Perception | 4 | 2019 | 569 | 0.090 |
Why?
|
| Chlorpromazine | 2 | 2014 | 111 | 0.090 |
Why?
|
| Circadian Rhythm Signaling Peptides and Proteins | 1 | 2009 | 30 | 0.090 |
Why?
|
| Cohort Studies | 10 | 2022 | 40558 | 0.090 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1989 | 67 | 0.090 |
Why?
|
| Fixation, Ocular | 4 | 2008 | 251 | 0.090 |
Why?
|
| Circadian Rhythm | 3 | 2019 | 2624 | 0.090 |
Why?
|
| Paroxetine | 2 | 2000 | 182 | 0.090 |
Why?
|
| Pregnancy | 5 | 2023 | 29144 | 0.090 |
Why?
|
| Psychotherapy, Group | 2 | 2010 | 406 | 0.090 |
Why?
|
| Magic | 1 | 1989 | 12 | 0.090 |
Why?
|
| Boston | 3 | 2021 | 9312 | 0.090 |
Why?
|
| Sensory Gating | 1 | 2009 | 47 | 0.090 |
Why?
|
| Illness Behavior | 1 | 2009 | 22 | 0.090 |
Why?
|
| Child Development | 3 | 2013 | 2223 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 941 | 0.090 |
Why?
|
| Comorbidity | 9 | 2009 | 10388 | 0.090 |
Why?
|
| Thyrotropin | 3 | 1988 | 849 | 0.090 |
Why?
|
| Patient Participation | 1 | 2018 | 1457 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15159 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 1312 | 0.080 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 12244 | 0.080 |
Why?
|
| Ganglia | 1 | 2008 | 89 | 0.080 |
Why?
|
| Oculomotor Muscles | 2 | 2005 | 371 | 0.080 |
Why?
|
| Borderline Personality Disorder | 2 | 2007 | 736 | 0.080 |
Why?
|
| Phosphatidylethanolamines | 3 | 2013 | 134 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2021 | 3318 | 0.080 |
Why?
|
| Medicine, Traditional | 1 | 1989 | 91 | 0.080 |
Why?
|
| Cause of Death | 1 | 2019 | 3582 | 0.080 |
Why?
|
| Disabled Children | 1 | 2011 | 247 | 0.080 |
Why?
|
| Patient Preference | 1 | 2015 | 889 | 0.080 |
Why?
|
| Extrapyramidal Tracts | 1 | 2008 | 18 | 0.080 |
Why?
|
| Diagnosis, Differential | 8 | 2021 | 12961 | 0.080 |
Why?
|
| Discriminant Analysis | 3 | 2013 | 235 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2023 | 2029 | 0.080 |
Why?
|
| Nervous System Malformations | 1 | 2010 | 247 | 0.080 |
Why?
|
| Tic Disorders | 1 | 1988 | 127 | 0.080 |
Why?
|
| Ear, External | 1 | 1988 | 161 | 0.080 |
Why?
|
| Hand Dermatoses | 1 | 1988 | 61 | 0.080 |
Why?
|
| Diazepam | 1 | 1988 | 205 | 0.080 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3778 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 850 | 0.080 |
Why?
|
| Transsexualism | 1 | 1991 | 178 | 0.080 |
Why?
|
| Prenatal Care | 1 | 2015 | 1092 | 0.080 |
Why?
|
| Mental Recall | 2 | 2014 | 1206 | 0.080 |
Why?
|
| Thyroid Function Tests | 1 | 1988 | 286 | 0.080 |
Why?
|
| Wakefulness | 3 | 2005 | 1245 | 0.080 |
Why?
|
| Isoenzymes | 1 | 1992 | 1728 | 0.070 |
Why?
|
| Dihydroergotoxine | 1 | 1986 | 21 | 0.070 |
Why?
|
| Weight Gain | 2 | 2008 | 2293 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2015 | 3207 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2014 | 7730 | 0.070 |
Why?
|
| Phencyclidine Abuse | 1 | 1986 | 8 | 0.070 |
Why?
|
| Chronic Disease | 6 | 2012 | 9145 | 0.070 |
Why?
|
| Cyclothymic Disorder | 2 | 2017 | 41 | 0.070 |
Why?
|
| Coronary Artery Disease | 2 | 2021 | 6486 | 0.070 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 1987 | 89 | 0.070 |
Why?
|
| Proteins | 2 | 2012 | 6100 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 3610 | 0.070 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 1708 | 0.070 |
Why?
|
| Models, Theoretical | 4 | 2021 | 3589 | 0.070 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2008 | 143 | 0.070 |
Why?
|
| Communication | 1 | 2021 | 3750 | 0.070 |
Why?
|
| Platelet Aggregation | 2 | 2007 | 798 | 0.070 |
Why?
|
| Child Behavior Disorders | 2 | 2010 | 807 | 0.070 |
Why?
|
| Phencyclidine | 1 | 1986 | 61 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2010 | 600 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1410 | 0.070 |
Why?
|
| Myelin Sheath | 4 | 2021 | 652 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 8642 | 0.070 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2011 | 582 | 0.070 |
Why?
|
| MEDLINE | 1 | 2006 | 125 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2014 | 1379 | 0.070 |
Why?
|
| Trihexyphenidyl | 1 | 1985 | 4 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2013 | 1889 | 0.070 |
Why?
|
| Orientation | 1 | 2008 | 327 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 2008 | 449 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2011 | 1124 | 0.070 |
Why?
|
| Demography | 4 | 2021 | 1656 | 0.070 |
Why?
|
| Cholinergic Fibers | 1 | 1985 | 68 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2023 | 25628 | 0.070 |
Why?
|
| Vitamin D Deficiency | 1 | 2015 | 1343 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2011 | 1063 | 0.070 |
Why?
|
| Child Behavior | 1 | 2011 | 839 | 0.070 |
Why?
|
| Publishing | 1 | 2013 | 833 | 0.070 |
Why?
|
| Apolipoproteins D | 1 | 2005 | 14 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3338 | 0.070 |
Why?
|
| Pedigree | 3 | 2012 | 4642 | 0.070 |
Why?
|
| Electrocardiography | 4 | 2009 | 6442 | 0.060 |
Why?
|
| Diagnostic Imaging | 2 | 2009 | 3508 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3154 | 0.060 |
Why?
|
| Long QT Syndrome | 1 | 2009 | 453 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2014 | 3203 | 0.060 |
Why?
|
| Prevalence | 3 | 2016 | 15221 | 0.060 |
Why?
|
| Dendrites | 1 | 2007 | 485 | 0.060 |
Why?
|
| Bibliometrics | 1 | 2008 | 339 | 0.060 |
Why?
|
| Students | 1 | 2014 | 1651 | 0.060 |
Why?
|
| Amino Acids, Essential | 1 | 2004 | 24 | 0.060 |
Why?
|
| Vitamin B 12 | 1 | 2007 | 527 | 0.060 |
Why?
|
| Health Status | 1 | 2017 | 4033 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2016 | 9849 | 0.060 |
Why?
|
| Facial Muscles | 1 | 2004 | 157 | 0.060 |
Why?
|
| Gene Frequency | 3 | 2020 | 3587 | 0.060 |
Why?
|
| ROC Curve | 1 | 2011 | 3527 | 0.060 |
Why?
|
| Nonlinear Dynamics | 2 | 2017 | 502 | 0.060 |
Why?
|
| Trifluoperazine | 1 | 1983 | 40 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2010 | 1366 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 2076 | 0.060 |
Why?
|
| Fatty Acids, Essential | 1 | 2003 | 95 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 5749 | 0.060 |
Why?
|
| Behavior Control | 1 | 2023 | 45 | 0.060 |
Why?
|
| Cytokines | 1 | 2018 | 7323 | 0.060 |
Why?
|
| Depersonalization | 1 | 1983 | 39 | 0.060 |
Why?
|
| Motor Skills Disorders | 1 | 2003 | 90 | 0.050 |
Why?
|
| Verbal Behavior | 1 | 2004 | 339 | 0.050 |
Why?
|
| Blinking | 1 | 1983 | 138 | 0.050 |
Why?
|
| Consensus | 3 | 2018 | 2960 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2011 | 2132 | 0.050 |
Why?
|
| Acute Disease | 4 | 2020 | 7147 | 0.050 |
Why?
|
| Algorithms | 4 | 2023 | 13882 | 0.050 |
Why?
|
| Cadmium | 1 | 2023 | 212 | 0.050 |
Why?
|
| Matched-Pair Analysis | 2 | 2005 | 288 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 2916 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2008 | 1443 | 0.050 |
Why?
|
| Psychological Techniques | 1 | 2021 | 45 | 0.050 |
Why?
|
| Disability Evaluation | 2 | 2008 | 1827 | 0.050 |
Why?
|
| Cues | 2 | 2007 | 875 | 0.050 |
Why?
|
| Astronomy | 1 | 1981 | 5 | 0.050 |
Why?
|
| Vitamin D | 1 | 2015 | 3224 | 0.050 |
Why?
|
| Pennsylvania | 1 | 2003 | 613 | 0.050 |
Why?
|
| Catecholamines | 2 | 1999 | 387 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 1343 | 0.050 |
Why?
|
| Students, Medical | 1 | 1994 | 1862 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 1868 | 0.050 |
Why?
|
| Software | 4 | 2008 | 4442 | 0.050 |
Why?
|
| Probability | 3 | 2023 | 2506 | 0.050 |
Why?
|
| Axilla | 1 | 2023 | 595 | 0.050 |
Why?
|
| Somatosensory Cortex | 1 | 2005 | 528 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 3 | 2014 | 1534 | 0.050 |
Why?
|
| Radiography | 3 | 2007 | 7023 | 0.050 |
Why?
|
| Isotopes | 1 | 2000 | 124 | 0.050 |
Why?
|
| Protein Binding | 1 | 2012 | 9384 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 2556 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 177 | 0.050 |
Why?
|
| Pons | 1 | 2001 | 245 | 0.040 |
Why?
|
| Neurons | 4 | 2007 | 9340 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2015 | 4687 | 0.040 |
Why?
|
| Genome | 1 | 2008 | 1807 | 0.040 |
Why?
|
| Medulla Oblongata | 1 | 2001 | 243 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 2232 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2016 | 295 | 0.040 |
Why?
|
| Meningioma | 1 | 1988 | 1209 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2012 | 2987 | 0.040 |
Why?
|
| Cell Division | 1 | 2007 | 4569 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 2269 | 0.040 |
Why?
|
| Meningeal Neoplasms | 1 | 1988 | 1241 | 0.040 |
Why?
|
| Physician's Role | 1 | 2006 | 943 | 0.040 |
Why?
|
| Plants | 1 | 2020 | 316 | 0.040 |
Why?
|
| Hospitalization | 3 | 2024 | 10259 | 0.040 |
Why?
|
| Arousal | 3 | 1997 | 1164 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2021 | 41005 | 0.040 |
Why?
|
| Acoustics | 1 | 2019 | 240 | 0.040 |
Why?
|
| Consumer Advocacy | 1 | 2018 | 81 | 0.040 |
Why?
|
| Parent-Child Relations | 1 | 1983 | 747 | 0.040 |
Why?
|
| Echo-Planar Imaging | 1 | 2002 | 659 | 0.040 |
Why?
|
| Cities | 1 | 2020 | 513 | 0.040 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 1998 | 141 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1999 | 438 | 0.040 |
Why?
|
| Puberty | 1 | 2001 | 490 | 0.040 |
Why?
|
| Visual Fields | 2 | 2009 | 1047 | 0.040 |
Why?
|
| Brain Damage, Chronic | 2 | 1996 | 265 | 0.040 |
Why?
|
| Magnetics | 1 | 1981 | 606 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2012 | 1572 | 0.040 |
Why?
|
| Developing Countries | 2 | 2020 | 2815 | 0.040 |
Why?
|
| Nasal Provocation Tests | 1 | 2017 | 9 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3873 | 0.040 |
Why?
|
| Reality Testing | 1 | 1997 | 26 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 595 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2018 | 77459 | 0.040 |
Why?
|
| Patient Admission | 2 | 1997 | 1380 | 0.040 |
Why?
|
| History, Medieval | 1 | 2017 | 63 | 0.040 |
Why?
|
| Episode of Care | 1 | 1998 | 126 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2018 | 162 | 0.040 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2018 | 238 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2019 | 306 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 252 | 0.040 |
Why?
|
| Patient Rights | 1 | 2017 | 126 | 0.040 |
Why?
|
| Glutathione Peroxidase | 1 | 2018 | 255 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2007 | 2212 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 1981 | 482 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2007 | 2509 | 0.030 |
Why?
|
| Gene Expression | 2 | 2012 | 7798 | 0.030 |
Why?
|
| Angiography | 1 | 2022 | 1639 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 2278 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3921 | 0.030 |
Why?
|
| Health Occupations | 1 | 2017 | 224 | 0.030 |
Why?
|
| Sampling Studies | 1 | 1997 | 623 | 0.030 |
Why?
|
| Binding Sites | 1 | 2005 | 6111 | 0.030 |
Why?
|
| Image Enhancement | 2 | 2004 | 2921 | 0.030 |
Why?
|
| Physical Examination | 1 | 2002 | 1237 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2019 | 1137 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2017 | 454 | 0.030 |
Why?
|
| Choline | 2 | 2008 | 493 | 0.030 |
Why?
|
| Age Distribution | 1 | 2021 | 2902 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2012 | 7882 | 0.030 |
Why?
|
| Personality Inventory | 2 | 2013 | 1030 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2011 | 23406 | 0.030 |
Why?
|
| Tourette Syndrome | 1 | 1998 | 379 | 0.030 |
Why?
|
| Feedback | 1 | 2018 | 795 | 0.030 |
Why?
|
| Relaxation | 1 | 1994 | 50 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1980 | 685 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2020 | 896 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2007 | 6234 | 0.030 |
Why?
|
| Developmental Disabilities | 2 | 2005 | 1456 | 0.030 |
Why?
|
| Glycerylphosphorylcholine | 1 | 2013 | 25 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2021 | 1167 | 0.030 |
Why?
|
| Movement | 1 | 2021 | 1471 | 0.030 |
Why?
|
| Perception | 1 | 2000 | 1198 | 0.030 |
Why?
|
| Educational Status | 3 | 2013 | 2540 | 0.030 |
Why?
|
| Patient Compliance | 2 | 2018 | 2685 | 0.030 |
Why?
|
| Receptors, Dopamine | 1 | 1994 | 295 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 783 | 0.030 |
Why?
|
| Rural Population | 2 | 2020 | 2207 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 1983 | 1771 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 2018 | 737 | 0.030 |
Why?
|
| Alleles | 2 | 2019 | 6933 | 0.030 |
Why?
|
| Receptors, Calcitriol | 1 | 2015 | 348 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2018 | 12025 | 0.030 |
Why?
|
| Axons | 1 | 2021 | 1685 | 0.030 |
Why?
|
| Specialty Boards | 1 | 1994 | 227 | 0.030 |
Why?
|
| Electronic Mail | 1 | 2014 | 213 | 0.030 |
Why?
|
| Nuclear Family | 1 | 2013 | 318 | 0.030 |
Why?
|
| Smell | 1 | 1994 | 244 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2012 | 98 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 651 | 0.030 |
Why?
|
| Marital Status | 1 | 2013 | 437 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2013 | 227 | 0.030 |
Why?
|
| Parkinson Disease | 1 | 1986 | 2775 | 0.030 |
Why?
|
| Life Change Events | 1 | 2017 | 938 | 0.030 |
Why?
|
| Cardiolipins | 1 | 1991 | 88 | 0.030 |
Why?
|
| Health Promotion | 1 | 2024 | 2205 | 0.030 |
Why?
|
| Longevity | 1 | 2019 | 1071 | 0.030 |
Why?
|
| Pyramidal Cells | 1 | 1994 | 363 | 0.030 |
Why?
|
| Multigene Family | 1 | 2015 | 1102 | 0.020 |
Why?
|
| Globus Pallidus | 2 | 2003 | 253 | 0.020 |
Why?
|
| Dystonia | 1 | 1994 | 363 | 0.020 |
Why?
|
| Uric Acid | 2 | 2010 | 766 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 1991 | 163 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1991 | 20130 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2022 | 2063 | 0.020 |
Why?
|
| Hypoxanthine | 1 | 2010 | 28 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2012 | 411 | 0.020 |
Why?
|
| Genomic Imprinting | 1 | 2012 | 328 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2015 | 1200 | 0.020 |
Why?
|
| Homeostasis | 2 | 2012 | 3339 | 0.020 |
Why?
|
| Guanosine | 1 | 2010 | 61 | 0.020 |
Why?
|
| Electrodes | 1 | 2012 | 619 | 0.020 |
Why?
|
| Length of Stay | 1 | 2023 | 6311 | 0.020 |
Why?
|
| Xanthines | 1 | 2010 | 121 | 0.020 |
Why?
|
| Ribonucleosides | 1 | 2010 | 82 | 0.020 |
Why?
|
| Cell Count | 1 | 1994 | 1856 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2006 | 4557 | 0.020 |
Why?
|
| Empathy | 1 | 1994 | 474 | 0.020 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2009 | 90 | 0.020 |
Why?
|
| Vocabulary | 1 | 2009 | 169 | 0.020 |
Why?
|
| Stereotyped Behavior | 1 | 2009 | 136 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2022 | 3486 | 0.020 |
Why?
|
| Basal Ganglia Diseases | 1 | 1989 | 149 | 0.020 |
Why?
|
| Neurogenesis | 1 | 2015 | 838 | 0.020 |
Why?
|
| Metabolism | 1 | 2010 | 196 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 1997 | 0.020 |
Why?
|
| Clinical Clerkship | 1 | 1994 | 532 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 187 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2015 | 3144 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2009 | 447 | 0.020 |
Why?
|
| Forecasting | 1 | 2017 | 2951 | 0.020 |
Why?
|
| Seizures | 1 | 1981 | 2859 | 0.020 |
Why?
|
| Sensory Deprivation | 1 | 1988 | 109 | 0.020 |
Why?
|
| Face | 1 | 2014 | 994 | 0.020 |
Why?
|
| Nomifensine | 1 | 1987 | 15 | 0.020 |
Why?
|
| Methionine | 1 | 2010 | 590 | 0.020 |
Why?
|
| Perphenazine | 1 | 2007 | 34 | 0.020 |
Why?
|
| PubMed | 1 | 2008 | 123 | 0.020 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 1151 | 0.020 |
Why?
|
| Educational Measurement | 1 | 1994 | 1210 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1132 | 0.020 |
Why?
|
| Ear Diseases | 1 | 1988 | 170 | 0.020 |
Why?
|
| Stomatitis, Aphthous | 1 | 1987 | 53 | 0.020 |
Why?
|
| Causality | 2 | 2004 | 1275 | 0.020 |
Why?
|
| Alzheimer Disease | 2 | 1993 | 8038 | 0.020 |
Why?
|
| Psychoanalytic Interpretation | 1 | 1986 | 57 | 0.020 |
Why?
|
| Oculomotor Nerve | 1 | 2006 | 74 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1991 | 1537 | 0.020 |
Why?
|
| Agoraphobia | 1 | 1986 | 179 | 0.020 |
Why?
|
| Triiodothyronine | 1 | 1988 | 494 | 0.020 |
Why?
|
| Perceptual Disorders | 1 | 2008 | 196 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1988 | 15295 | 0.020 |
Why?
|
| Pulmonary Atelectasis | 1 | 1987 | 145 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2007 | 425 | 0.020 |
Why?
|
| Somatoform Disorders | 1 | 1989 | 423 | 0.020 |
Why?
|
| Mass Screening | 1 | 2021 | 5255 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 1254 | 0.020 |
Why?
|
| Language Development Disorders | 1 | 2007 | 196 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2020 | 6254 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 57776 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1504 | 0.020 |
Why?
|
| Gender Identity | 1 | 1991 | 687 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 1420 | 0.020 |
Why?
|
| Legislation, Drug | 1 | 1987 | 206 | 0.020 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2006 | 304 | 0.020 |
Why?
|
| England | 1 | 1986 | 522 | 0.020 |
Why?
|
| Thyroxine | 1 | 1988 | 667 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2006 | 569 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 211 | 0.010 |
Why?
|
| Blindness | 1 | 1988 | 615 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2013 | 1344 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2012 | 2308 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 81202 | 0.010 |
Why?
|
| Metabolomics | 1 | 2012 | 1485 | 0.010 |
Why?
|
| Genetic Load | 1 | 2003 | 15 | 0.010 |
Why?
|
| Melatonin | 1 | 2009 | 721 | 0.010 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1983 | 148 | 0.010 |
Why?
|
| Cotinine | 1 | 2004 | 206 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1991 | 2036 | 0.010 |
Why?
|
| Asia, Southeastern | 1 | 1983 | 111 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1987 | 2274 | 0.010 |
Why?
|
| Valproic Acid | 1 | 2005 | 445 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2009 | 1783 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 1438 | 0.010 |
Why?
|
| Computer Graphics | 1 | 2004 | 361 | 0.010 |
Why?
|
| Models, Biological | 1 | 2019 | 9584 | 0.010 |
Why?
|
| Automation | 1 | 2004 | 584 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2012 | 12720 | 0.010 |
Why?
|
| Occupations | 1 | 2004 | 517 | 0.010 |
Why?
|
| Astronomical Phenomena | 1 | 1981 | 1 | 0.010 |
Why?
|
| Penis | 1 | 1983 | 217 | 0.010 |
Why?
|
| Bilirubin | 1 | 2003 | 425 | 0.010 |
Why?
|
| Iron | 1 | 1989 | 1774 | 0.010 |
Why?
|
| Electroshock | 1 | 1981 | 122 | 0.010 |
Why?
|
| Nerve Degeneration | 1 | 2005 | 748 | 0.010 |
Why?
|
| Albumins | 1 | 2003 | 568 | 0.010 |
Why?
|
| Computational Biology | 1 | 2012 | 3519 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1991 | 4561 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 3647 | 0.010 |
Why?
|
| Dementia | 1 | 1993 | 2518 | 0.010 |
Why?
|
| Body Image | 1 | 1983 | 610 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 3493 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2004 | 875 | 0.010 |
Why?
|
| Smoking | 2 | 2010 | 8987 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 5857 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1999 | 909 | 0.010 |
Why?
|
| Child Abuse, Sexual | 1 | 1999 | 383 | 0.010 |
Why?
|
| Patients | 1 | 2002 | 900 | 0.010 |
Why?
|
| Epinephrine | 1 | 1999 | 792 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2005 | 1916 | 0.010 |
Why?
|
| Biperiden | 1 | 1994 | 1 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 3177 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 4328 | 0.010 |
Why?
|
| New York | 1 | 1997 | 886 | 0.010 |
Why?
|
| Sensory Thresholds | 1 | 1994 | 391 | 0.010 |
Why?
|
| Diet | 1 | 2010 | 7937 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1997 | 2634 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2003 | 2408 | 0.010 |
Why?
|
| Placebos | 1 | 1994 | 1676 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 20950 | 0.010 |
Why?
|
| Phenelzine | 1 | 1987 | 28 | 0.000 |
Why?
|
| Symbolism | 1 | 1986 | 34 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1997 | 2708 | 0.000 |
Why?
|
| Lithium Carbonate | 1 | 1986 | 184 | 0.000 |
Why?
|
| Acetylcholine | 1 | 1987 | 621 | 0.000 |
Why?
|
| Rats | 1 | 1981 | 24252 | 0.000 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 1983 | 103 | 0.000 |
Why?
|
| Autoimmune Diseases | 1 | 1991 | 2133 | 0.000 |
Why?
|